ClinicalTrials.gg
TerminatedNCT00472953iINHALE 8Updated Mar 1, 2017

Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of inhaled human insulin and insulin aspart in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Terminated at 27 sites in 7 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2017-03-01.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus.

Enrollment
23rd of 41
38 · median 60
Started
2007
with 8 others
Phase 3
18 of 41
none open now
Registered
12th of 41
by date
Lead sponsor
19 of 41
Novo Nordisk A/S

Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, this one is the 23rd largest by enrollment, is one of 9 that started in 2007, is one of 18 in phase 3, and was the 12th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, or all of them as a file.
02

Study summary

This trial is conducted in Europe, Asia and South America. A one-year clinical trial to compare the safety of inhaled human insulin to subcutaneous insulin aspart in subjects with type 1 or type 2 diabetes and chronic obstructive pulmonary disease (COPD).

Read the detailed description

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 or type 2 diabetes
  • lower or equal to 11.0 %
  • (BMI) lower or equal to 40.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Recurrent severe hypoglycaemia
  • Current smoking or smoking within the last 6 months
  • Other pulmonary disease including asthma
  • Proliferative retinopathy or maculopathy requiring acute treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    A

    Drug: inhaled human insulin

  • Active comparator
    B

    Drug: insulin aspart

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate pulmonary safety comparing inhaled insulin to subcutaneous injections

    Time frame: After one year

Secondary outcomes

  1. Patient Reported Outcomes

    Time frame: After one year

  2. Diabetes control measured by change in HbA1c from baseline

    Time frame: After one year

  3. Preprandial Insulin Doses

    Time frame: After one year

07

Study locations

27 sites
  • Novo Nordisk Investigational Site
    Buenos Aires, B1636DSU, Argentina
  • Novo Nordisk Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • Novo Nordisk Investigational Site
    Ciudad de Buenos Aires, 1280, Argentina
  • Novo Nordisk Investigational Site
    Chandigarh, Punjab 160012, India
  • Novo Nordisk Investigational Site
    Vellore, Tamil Nadu 632004, India
  • Novo Nordisk Investigational Site
    Kolkata, West Bengal 700020, India
  • Novo Nordisk Investigational Site
    Hyderabad, 600034, India
  • Novo Nordisk Investigational Site
    Mumbai, 400 067, India
  • Novo Nordisk Investigational Site
    Pune, 411011, India
  • Novo Nordisk Investigational Site
    Bucharest, 020475, Romania
  • Novo Nordisk Investigational Site
    Bucharest, 020992, Romania
  • Novo Nordisk Investigational Site
    Kosice, 04190, Slovakia
  • Novo Nordisk Investigational Site
    Lubochna, 03491, Slovakia
  • Novo Nordisk Investigational Site
    Moldava nad Bodvou, 045 01, Slovakia
  • Novo Nordisk Investigational Site
    Zilina, 01001, Slovakia
  • Novo Nordisk Investigational Site
    Zilina, 01207, Slovakia
  • Novo Nordisk Investigational Site
    Changhua, 500, Taiwan
  • Novo Nordisk Investigational Site
    Chiayi City, 600, Taiwan
  • Novo Nordisk Investigational Site
    Taipei, 231, Taiwan
  • Novo Nordisk Investigational Site
    Bangkok, 10330, Thailand
  • Novo Nordisk Investigational Site
    Bangkok, 10700, Thailand
  • Novo Nordisk Investigational Site
    Erzurum, 25240, Turkey
  • Novo Nordisk Investigational Site
    Gaziantep, 27070, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34400, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34722, Turkey
  • Novo Nordisk Investigational Site
    Istanbul, 34890, Turkey
  • Novo Nordisk Investigational Site
    Kocaeli, 41380, Turkey
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2007 to primary completion in Mar 2008, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2007
First posted
May 14, 2007
StartActual
May 15, 2007
Primary completionActual
Mar 5, 2008
CompletionActual
Mar 5, 2008
Last update
Mar 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00472953
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 14, 2007
Start date
May 15, 2007
Primary completion
Mar 5, 2008
Completion
Mar 5, 2008
Last update
Mar 1, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion